{"filing":{"accession_number":"0001193125-26-330804","cik":"0001623526","ticker":"STOK","company_name":"Stoke Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-03","report_date":"2026-08-03","primary_document":"d135735d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1623526/000119312526330804/d135735d8k.htm"},"events":[{"id":23233,"run_id":21007,"accession_number":"0001193125-26-330804","anchor_item_number":"8.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"The Company filed a prospectus supplement on August 3, 2026 under its at-the-market (ATM) offering program with Cantor Fitzgerald, authorizing the offer and sale of up to $200,000,000 of common stock. This is a dilutive equity issuance under an ATM facility, which is material to investors as it signals potential capital raising and shareholder dilution. The filing of the prospectus supplement activates the offering authority and represents a material capital markets event.","company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","filing_date":"2026-08-03","form":"8-K","submitted_at":null,"items":[{"id":23408,"accession_number":"0001193125-26-330804","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Company filed a prospectus supplement on August 3, 2026 under its at-the-market (ATM) offering program with Cantor Fitzgerald, authorizing the offer and sale of up to $200,000,000 of common stock. This is a dilutive equity issuance under an ATM facility, which is material to investors as it signals potential capital raising and shareholder dilution. The filing of the prospectus supplement activates the offering authority and represents a material capital markets event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T00:49:42.947399+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":23408,"accession_number":"0001193125-26-330804","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Company filed a prospectus supplement on August 3, 2026 under its at-the-market (ATM) offering program with Cantor Fitzgerald, authorizing the offer and sale of up to $200,000,000 of common stock. This is a dilutive equity issuance under an ATM facility, which is material to investors as it signals potential capital raising and shareholder dilution. The filing of the prospectus supplement activates the offering authority and represents a material capital markets event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T00:49:42.947399+00:00","company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","filing_date":"2026-08-03"}]}